 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | podentamig (MK-4002) / Merck (MSD)
Trial primary completion date: Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (HPN217) (clinicaltrials.gov) - Oct 15, 2024
P1, N=100, Active, not recruiting, Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Trial primary completion date: Dec 2024 --> Jun 2025
- | podentamig (MK-4002) / Merck (MSD)
Trial completion date: Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (HPN217) (clinicaltrials.gov) - Aug 9, 2024
P1, N=100, Active, not recruiting, Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Trial primary completion date: Dec 2024 --> Jun 2025 Trial completion date: May 2025 --> Nov 2025
- || podentamig (MK-4002) / Merck (MSD)
Trial completion date, Trial primary completion date: Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (HPN217) (clinicaltrials.gov) - May 27, 2024
P1, N=97, Active, not recruiting, Sponsor: Harpoon Therapeutics
Trial completion date: May 2025 --> Nov 2025 Trial completion date: Jun 2024 --> May 2025 | Trial primary completion date: Jan 2024 --> Dec 2024
- HPN-217 / Harpoon Therap
Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC (Grand Hyatt - Seaport Ballroom ABCD) - Nov 3, 2023 - Abstract #ASH2023ASH_5194;
P1
Additional follow up of recently enrolled pts in 12 mg and 24 mg cohorts will inform the choice of the RP2D(s), and complete data on all pts enrolled will be presented. NCT04184050
- || podentamig (MK-4002) / Merck (MSD)
Enrollment closed, Enrollment change: Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (HPN217) (clinicaltrials.gov) - Oct 1, 2023
P1, N=97, Active, not recruiting, Sponsor: Harpoon Therapeutics
NCT04184050 Recruiting --> Active, not recruiting | N=70 --> 97
- HPN-217 / Harpoon Therap, AbbVie
Ongoing Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC (In Person) - Sep 10, 2023 - Abstract #IMW2023IMW_565;
P1
The 12 mg QW regimen is well tolerated with a manageable adverse event profile, low rates of CRS (16%) and robust early clinical activity (58% ORR). Evaluation of regimens using 24 mg QW and Q2W is ongoing to inform the choice of an RP2D(s).
- HPN-217 / Harpoon Therap, AbbVie
Anti-tumor activity of HPN217, a BCMA-targeting tri-specific T cell engager, is enhanced by ?-secretase inhibitors in preclinical models (Section 21; Poster Board #15) - Mar 14, 2023 - Abstract #AACR2023AACR_7421;
P1
By contrast, the combination of HPN217 and LY3039478 led to a significant increase in survival compared to vehicle or either monotherapy, with a median survival of 43 days. Taken together these results demonstrate the potential utility of GSIs to enhance the anti-tumor activity of HPN217 and supports further investigation of this combinatorial approach in patients.
- |||| HPN-217 / Harpoon Therap, AbbVie
Clinical: ASH 2022 | Phase I study of HPN217 in patients with R/R multiple myeloma #mmsm #USMIRC #myeloma https://t.co/CuaYUggv2i #MedTwitter (Twitter) - Mar 9, 2023
- ||||| HPN-217 / Harpoon Therap, AbbVie
Clinical: Al-Ola A. Abdallah, MD, discusses updated data with HPN217 in relapsed/refractory multiple myeloma and next steps for the investigation as well as sequencing of BCMA-targeted therapies for this patient population. @Abdallah81MD @KUHospital #mmsm https://t.co/TXQF3c4bDv (Twitter) - Feb 26, 2023
- ||||| HPN-217 / Harpoon Therap, AbbVie
Clinical: TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results - What can this data from a phase 1 study of HPN217 do for patients with RRMM? @Abdallah81MD @KUMedCenter #ASH22 #RRMM Listen and Share the Audio Podcast Here: https://t.co/8LEZs0unSV (Twitter) - Jan 5, 2023
- ||||| HPN-217 / Harpoon Therap, AbbVie
Clinical: TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results - What can this data from a phase 1 study of HPN217 do for patients with RRMM? @Abdallah81MD @KUMedCenter #ASH22 #RRMM Read and Share the Article Here: https://t.co/OyzYtb2VTo (Twitter) - Jan 5, 2023
- ||||| HPN-217 / Harpoon Therap, AbbVie
Clinical, Video: TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results - What can this data from a phase 1 study of HPN217 do for patients with RRMM? @Abdallah81MD @KUMedCenter #ASH22 #RRMM Watch and Share the Video Here: https://t.co/cQuqEmuNnh (Twitter) - Jan 5, 2023
- |||| HPN-217 / Harpoon Therap, AbbVie
Clinical: On @OncLive: Dr. Abdallah discusses Interim Efficacy Data on HPN217 in R/R Multiple Myeloma. @Abdallah81MD https://t.co/AGdUQabThg (Twitter) - Jan 4, 2023
- ||||| HPN-217 / Harpoon Therap, AbbVie
Clinical, P1 data: Phase 1 Study of HPN217:TriTAC Targeting BBCMA for RRMM: efficacy in RRMM; n=62; Triple Class 78%; 20% BCMA exposed; the higher dose showed a RR of 77% #mmsm #ASH22 @ASH_hematology #MedTwitter (Twitter) - Dec 11, 2022
- || HPN-217 / Harpoon Therap, AbbVie
HPN217 data justifying $HARP's 20% run-up on Friday? #ASH22 (Twitter) - Dec 11, 2022
- |||| HPN-217 / Harpoon Therap, AbbVie
Updated Interim Results from a Phase 1 Study of HPN217, A Tri-Specific T Cell Activating Construct Targeting BCMA for RRMM https://t.co/yHVMPL0oIg #mmsm #ASH22 #myeloma #USMIRC #MedTwitter #MedEd (Twitter) - Nov 5, 2022
- HPN-217 / Harpoon Therap, AbbVie
Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM) (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_4618;
P1
Changes in biomarkers associated with clinical responses were observed. NCT04184050
- || podentamig (MK-4002) / Merck (MSD)
Phase classification, Enrollment change: Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (HPN217) (clinicaltrials.gov) - Jul 25, 2022
P1, N=70, Recruiting, Sponsor: Harpoon Therapeutics
NCT04184050 Phase classification: P1/2 --> P1 | N=114 --> 70
- HPN217 / Harpoon Therap, AbbVie
An Interim Report on a Phase 1/2 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen for the Treatment of Relapsed/Refractory Multiple Myeloma (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_3235;
P1/2
Premedication to minimize cytokine release syndrome (CRS) includes dexamethasone, diphenhydramine, acetaminophen, and a proton pump inhibitor...Patients treated received a median of 8 (range of 4 – 16) prior systemic regimens, including 5 patients who received prior BCMA-targeted belantamab mafodotin or orvacabtagene autoleucel...Dose escalation, including implementation of step dosing, with the goal of establishing an RP2D regimen, is ongoing. NCT04184050
- HPN217 / Harpoon Therap, AbbVie
The Effects of BCMA Expression, Soluble BCMA, and Combination Therapeutics on the Anti-Tumor Activity of HPN217, a BCMA-Targeting Tri-Specific T Cell Engager Against Multiple Myeloma (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_2744;
P1/2
Herein, we describe translational studies to examine factors that may impact the therapeutic efficacy of HPN217, including the target BCMA, in membrane-bound or soluble form, and concomitant or combination therapeutics such as γ-secretase inhibitor (GSI) and dexamethasone...Interestingly, treatment of MM cell line RPMI8226 with the GSI LY-3039478 for 24 hours increased the cell surface expression of BCMA by 3.6 folds...On the other hand, Dex had limited negative effect. HPN217 in combination with approved and experimental MM therapeutics is being evaluated in the 3DTEBM and MM.1S-Luc models.
- ||| podentamig (MK-4002) / Merck (MSD)
Enrollment change: Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (HPN217) (clinicaltrials.gov) - Sep 10, 2021
P1/2, N=114, Recruiting, Sponsor: Harpoon Therapeutics
HPN217 in combination with approved and experimental MM therapeutics is being evaluated in the 3DTEBM and MM.1S-Luc models. N=70 --> 114
- ||||| HPN217 / Harpoon Therap, AbbVie
Orphan drug: FDA Grants Orphan Drug Designation to BCMA-Targeted TriTAC HPN217 for Myeloma https://t.co/SKYDS8QCLg #mmsm (Twitter) - Jan 16, 2021
- HPN217 / Harpoon Therap, AbbVie
[VIRTUAL] HPN217-3001: A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217, a Bcma-Targeting T-Cell Engager, in Patients with Relapsed/Refractory Multiple Myeloma (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_1207;
P1/2
The study will also evaluate overall response rate (ORR) based on IMWG response criteria, progression-free survival (PFS) and overall survival (OS), duration of response (DOR), immunogenicity of HPN217, and other exploratory endpoints related to the mechanism of action of HPN217. (NCT04184050)
- ||| podentamig (MK-4002) / Merck (MSD)
Enrollment open: Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (HPN217) (clinicaltrials.gov) - Mar 16, 2020
P1/2, N=70, Recruiting, Sponsor: Harpoon Therapeutics
(NCT04184050) Not yet recruiting --> Recruiting
- |||| podentamig (MK-4002) / Merck (MSD)
New P1/2 trial: Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (HPN217) (clinicaltrials.gov) - Dec 2, 2019
P1/2, N=70, Not yet recruiting, Sponsor: Harpoon Therapeutics